This is why I love Medlab.
A "pot stock", but not a pot stock!
Great results!
Medlab receives positive NRGBiotic™ Phase IIa Depression trial independent preliminary results. • showed a significant reduction in depression scores from baseline • showed significant improvement in quality of life from baseline • safe and tolerable, with NO reported adverse effects Medlab Clinical (ASX: MDC), a company with a portfolio of novel pharmaceutical candidates enhanced by its patented delivery platform and used for the treatment of chronic pain and disease, has received a positive preliminary analysis of a Phase IIa clinical trial to support the expanded use of Medlab’s probiotic NRGBiotic™ in relation to helping treat major depression. Medlab’s Director of Medical Research, Prof Luis Vitetta, said: “The preliminary analysis on the group of patients who were administered NRGBiotic™ in combination with the patient’s prescribed anti-depressant medication, showed a significant reduction in depression scores from baseline to eight weeks – a statistically significant, preliminary result. ” The other standout points were the confirmed safety and tolerability factors for the NRGBiotic™ administered cohort that presented with no adverse effects from the probiotic formulation.
- Forums
- ASX - By Stock
- MDC
- Ann: Medlab Receives Positive Depression Trial Prelim Results
Ann: Medlab Receives Positive Depression Trial Prelim Results, page-2
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MDC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$6.60 |
Change
0.000(0.00%) |
Mkt cap ! $15.07M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
MDC (ASX) Chart |
Day chart unavailable
The Watchlist
EL8
ELEVATE URANIUM LTD
Murray Hill, MD & CEO
Murray Hill
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online